New study shows RNA polymerase I halts at abasic DNA damage, helping prevent faulty rRNA production and exposing lesions for ...

A promising new treatment to combat "undruggable" cancers has been green-lit for a human trial in 2025. It's hoped the novel ...

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant ...

RNA Pol II Inhibitor-Bacteria is under clinical development by Hamlet Pharma and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase ...

Thus, chromatin-based control of the Pol II elongation rate is a potential mechanism to regulate alternative polyadenylation in response to genetic or environmental changes. The RNA polymerase II (Pol ...

The transcription of ribosomal RNA by RNA Polymerase I (Pol I) is an essential step for cells to grow and thus is considered a therapeutic target for cancer treatment. Second-gen RNA pol I inhibitor ...

The authors first sought to understand how these drugs affected RNA Pol II dynamics and assessed genomic distribution of both paused and elongating Pol II using the Henikoff lab’s bread and butter ...

TERs are transcribed by RNA polymerase III (Pol III), while animal and ascomycete fungal TERs are transcribed by RNA Pol II and share biogenesis pathways with small nucleolar RNA (snoRNA ...

Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic ...

PORTAGE, Mich.--(BUSINESS WIRE)--Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic ...

RNA polymerase II (RNA Pol II) speed or elongation rate, i.e., the number of nucleotides synthesized per unit of time, is a major determinant of transcriptome composition. It controls ...